News and Trends 16 Sep 2019 Sepsis Diagnosed in 5 Minutes Instead of 24 Hours with Swiss Biotech’s Test A test for sepsis developed by the Swiss diagnostics company Abionic was able to predict within just five minutes which intensive care patients are likely to develop sepsis in a clinical study. In the pivotal study, Abionic trialed the blood test in 300 intensive care patients with a high risk of sepsis. Abionic found that […] September 16, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2019 Icelandic Company to Sequence 225,000 Genomes from UK Patients The Icelandic genomics company deCODE genetics has joined the UK’s Wellcome Sanger Institute in sequencing 450,000 genomes as part of a massive €224M (£200M) project organized by the UK Biobank initiative. The UK Biobank’s €224M grant includes €56M (£50M) from the UK government, €56M from the UK’s Wellcome Trust charity, and €112M (£100M) from big […] September 13, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 13 Sep 2019 This Biotech Makes Meat Substitutes from Crops Using Fungi We’re traveling to Glasgow, UK, this week. The biotech 3F BIO is using fungi to convert plant sugars into proteins in a process that uses less than half of the water and feed that farming animal meat requires. Mission: To turn plant sugars into proteins using fungi, which could help to feed the growing world’s […] September 13, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Inside Labiotech 12 Sep 2019 Prost🍺! Labiotech is the Main Media Partner of the 25th Edition of BIO-Europe! This is an extraordinary year for BIO-Europe, because it’s celebrating its 25th anniversary. Congratulations! 🎉 As Europe’s biggest biotech event, Bio-Europe attracted 4,300+ attendees from 2,300+ companies in 2018. What’s even more amazing is that they helped coordinate over 26,000 meetings where biotech professionals gathered around to partner with each other and foster innovation. Labiotech […] September 12, 2019 - 3 minutesmins - By Yi-Jen Chang Share WhatsApp Twitter Linkedin Email
More News! 12 Sep 2019 French Biotech to Develop Septic Shock Therapy with €39M Series B The French company Inotrem has raised €39M to fund an immunotherapy for septic shock, an often deadly condition caused by infections in the bloodstream. Led by the Hong Kong investor Morningside Ventures, the Series B round will finance a phase IIb trial of Inotrem’s lead candidate drug nangibotide, expected to start in November this year. […] September 12, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 12 Sep 2019 Interview: The Do’s & Don’ts of Branded Content in the Life Sciences Industry Although it’s becoming increasingly popular in life science marketing, branded content is still in its infancy. This does not mean it isn’t worth investing in. Quite the contrary: because it is fairly new, it is all the more exciting and can reach promising audiences within the life sciences industry. While other industries have long since […] September 12, 2019 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
More News! 11 Sep 2019 Dutch Company Raises €60M to Treat Inherited Inflammatory Disease The Dutch pharmaceutical company Pharvaris has raked in €60M in a Series B round to fund the clinical development of the first oral treatment for hereditary angioedema, a condition that causes swelling in the limbs and airways. The Series B round will fuel the clinical progress of Pharvaris’ oral small molecule treatment for hereditary angioedema, […] September 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2019 IBM’s Watson for Genomics Launches in First European Hospital The Hôpitaux Universitaires Genève in Switzerland will be the first European university hospital to implement IBM’s artificial intelligence to help doctors select treatments for complex cancer cases. “Artificial intelligence could empower our clinicians to increase the speed of diagnosing their patients,” said Rodolphe Meyer, who is responsible for the IT department of […] September 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2019 Grünenthal to Pay up to €900M for Chronic Low Back Pain Cell Therapy The German pharmaceutical company Grünenthal has licensed a donor cell therapy for chronic low back pain from the Australian biotech Mesoblast in a deal that could be worth over €900M. Under the terms of the deal, Grünenthal will gain exclusive rights to commercialize Mesoblast’s cell therapy for chronic low back pain in Europe and Latin […] September 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Sep 2019 Italian Biotech Raises €13M to Test Stem Cell Therapy for Cancer The Italian biotech Genenta Science has raised €13.2M in a private round to fund two ongoing phase I/II trials of its stem cell therapy Temferon for blood and brain cancer. Genenta Science will use the money to fund two European phase I/II trials, which the company launched in March. One trial is testing the stem […] September 11, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Sep 2019 Blood Test Increases Early Lung Cancer Diagnosis in UK Trial A blood test for anti-cancer antibodies, developed by the UK diagnostics company Oncimmune, detected more early cases of lung cancer than standard clinical monitoring procedures in a trial with more than 12,000 patients. Oncimmune’s trial recruited 12,209 patients with a high risk of developing lung cancer through smoking and family history, and monitored them for […] September 10, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Sep 2019 4BIO Capital Raises €45M Fund to Invest in Advanced Therapies The London-based life sciences investor 4BIO Capital has raised €45M in the first close of a fund to nurture companies developing advanced therapies such as gene and cell therapies. This is the first closing of 4BIO’s second fund, called 4BIO Ventures II, which is expected to total €136M ($150M) by late 2020. The fund will […] September 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email